NCT07103174CompletedPhase 2
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
A Phase II Clinical Study on the Efficacy and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of MG-K10 monotherapy in adult patients with moderate to severe AD, and to observe PK characteristics, PD effects and immunogenicity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 30 Jun 2025
- Start date
- 30 Jun 2025
- Primary completion date
- 9 Mar 2026
- Lead sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07103174
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 60
- From 30 Jun 2025 to the primary completion date, 9 Mar 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- There is evidence of active tuberculosis, or there has been evidence of active tuberculosis before and no appropriate documented treatment has been received
Other illness
- The subject currently has a diagnosis of other active skin diseases (such as psoriasis or lupus erythematosus) that may affect the evaluation of AD
- Patients with eye diseases that the researchers judged as unsuitable for inclusion
- Patients with malignant tumors within 5 years
- Confirm active parasitic infection
- Those with active hepatitis, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb), or positive for hepatitis C virus (HCV) antibody, or positive for HIV antibody, or positive for (TP-Ab)
Other
- Women who are breastfeeding or pregnant, or women planning to become pregnant or breastfeed during the study period
- Those who the researchers consider to have other circumstances that make them unsuitable to participate in the study
Who the study is looking for
- AD patients diagnosed in accordance with the consensus criteria of the American Academy of Dermatology (2014) had a history of AD or eczema diagnosis of ≥1 year
- The patient's response to topical medication treatment is insufficient, or it is medically inappropriate to use topical medication for treatment
- The subjects and their partners agreed to take effective contraceptive measures from signing the Informed Consent Form (ICF) until 6 months after the end of treatment, and had no plans for childbirth, sperm donation or egg donation
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Hangzhou First People's Hospital Coordinator of this site? Confirm its status | Zhejiang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.